Sulopenem etzadroxil is a penem antibacterial prodrug used to treat susceptible uncomplicated urinary tract infections in patients with no other treatment options. Like other beta-lactam antibacterials, it is a time-dependent inhibitor of bacterial cell wall synthesis.
- Mechanism
- Curator reviewed · 2 references
Sulopenem has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of sulopenem results from the inhibition of cell wall synthesis and is mediated through sulopenem binding to penicillin binding proteins (PBPs). Sulopenem's β-lactam ring alkylates the serine residues of PBPs, ultimately inhibiting peptidoglycan cross-linking.
- Primary indication
- Sulopenem etzadroxil is indicated in combination with probenecid for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral...Curator reviewed · 3 structured indications
- Formula / weight
- C19H27NO7S3 · 477.61 g/mol (avg)
- First approval
- United States, 2025
- Code names
- PF-03709270
- Brand names
Resolves to
NBPVNGWRLGHULH-CSOWVJSESA-NSMILES[H][C@]12SC(S[C@H]3CC[S@@+]([O-])C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(=O)OCOC(=O)C(CC)CCWhat you can answer from here — as of August 31, 2026
Which drugs share a target with Sulopenem etzadroxil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account